NASDAQ:EGRX Eagle Pharmaceuticals (EGRX) Stock Price, News & Analysis $5.50 0.00 (0.00%) (As of 07/5/2024 08:52 PM ET) Add Compare Share Share Today's Range$5.43▼$5.8550-Day Range$3.34▼$5.6052-Week Range$3.21▼$23.52Volume174,700 shsAverage Volume206,039 shsMarket Capitalization$71.45 millionP/E Ratio4.66Dividend YieldN/APrice Target$17.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Eagle Pharmaceuticals alerts: Email Address Eagle Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingSell1.00 Rating ScoreUpside/Downside209.1% Upside$17.00 Price TargetShort InterestHealthy8.70% of Float Sold ShortDividend StrengthN/ASustainability-2.29Upright™ Environmental ScoreNews Sentiment0.62Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.24 out of 5 starsMedical Sector143rd out of 879 stocksPharmaceutical Preparations Industry51st out of 417 stocks 2.5 Analyst's Opinion Consensus RatingEagle Pharmaceuticals has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageEagle Pharmaceuticals has received no research coverage in the past 90 days.Read more about Eagle Pharmaceuticals' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted8.70% of the float of Eagle Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverEagle Pharmaceuticals has a short interest ratio ("days to cover") of 6.7.Change versus previous monthShort interest in Eagle Pharmaceuticals has recently decreased by 7.93%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldEagle Pharmaceuticals does not currently pay a dividend.Dividend GrowthEagle Pharmaceuticals does not have a long track record of dividend growth. Previous Next 3.9 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreEagle Pharmaceuticals has received a 53.97% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Bendamustine", "Dantrolene", and "Pemetrexed" products. See details.Environmental SustainabilityThe Environmental Impact score for Eagle Pharmaceuticals is -2.29. Previous Next 2.6 News and Social Media Coverage News SentimentEagle Pharmaceuticals has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.74 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Eagle Pharmaceuticals this week, compared to 2 articles on an average week.Search Interest4 people have searched for EGRX on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Eagle Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Eagle Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders28.90% of the stock of Eagle Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions85.36% of the stock of Eagle Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Eagle Pharmaceuticals' insider trading history. Previous Next 1.9 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Eagle Pharmaceuticals is 4.66, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 125.84.Price to Earnings Ratio vs. SectorThe P/E ratio of Eagle Pharmaceuticals is 4.66, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 130.15.Price to Book Value per Share RatioEagle Pharmaceuticals has a P/B Ratio of 0.31. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Eagle Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaThe #1 Crypto That You Don’t Own… YetArtificial Intelligence has revolutionized the way we consume media and entertainment… And the A.I. wave has also created MASSIVE opportunities for savvy investors. One recent move stands out above all others: recently surfaced investments from three major media companies.Click here for all the details… About Eagle Pharmaceuticals Stock (NASDAQ:EGRX)Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.Read More EGRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EGRX Stock News HeadlinesJuly 1, 2024 | americanbankingnews.comEagle Pharmaceuticals (NASDAQ:EGRX) Coverage Initiated by Analysts at StockNews.comMay 22, 2024 | finanznachrichten.deEagle Pharmaceuticals, Inc.: Eagle Pharmaceuticals Announces Receipt of Delisting Notification from NasdaqJuly 8, 2024 | InvestorPlace (Ad)Must-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street veteran, Eric Fry… This mind-blowing new technology could be bigger than the iPhone.May 22, 2024 | globenewswire.comEagle Pharmaceuticals Announces Receipt of Delisting Notification from NasdaqApril 30, 2024 | finance.yahoo.comEagle Pharmaceuticals Announces a Trial in Progress Presentation of Phase 2/3 Study of Intravenous Amisulpride as Prevention of Postoperative Nausea and Vomiting in Pediatric Patients at the Upcoming Society for Ambulatory Anesthesia (SAMBA) 2024 Annual MeetingApril 15, 2024 | globenewswire.comEagle Pharmaceuticals to Present Additional Data from Phase III Trial Demonstrating Sustained Response of Amisulpride for the Rescue Treatment of Postoperative Nausea and Vomiting (PONV) at the Upcoming ASPAN 2024 National Conference in Orlando, FloridaApril 14, 2024 | investing.comEagle Pharmaceuticals faces potential Nasdaq delistingApril 13, 2024 | msn.comStocks Slightly Higher as US Mar PPI Climbs Less Than ExpectedJuly 8, 2024 | InvestorPlace (Ad)Must-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street veteran, Eric Fry… This mind-blowing new technology could be bigger than the iPhone.April 13, 2024 | msn.comStocks Mixed as Bond Yields ClimbApril 12, 2024 | finance.yahoo.comEagle Pharmaceuticals Announces Receipt of Notification of Deficiency from Nasdaq Regarding Requirement to Timely File Annual Report on Form 10-KApril 12, 2024 | globenewswire.comEagle Pharmaceuticals Announces Receipt of Notification of Deficiency from Nasdaq Regarding Requirement to Timely File Annual Report on Form 10-KFebruary 29, 2024 | msn.comEagle Pharmaceuticals to cut 36% of workforceFebruary 22, 2024 | benzinga.comEagle Pharmaceuticals Stock (NASDAQ:EGRX), Short Interest ReportFebruary 22, 2024 | benzinga.comEagle Pharmaceuticals Stock (NASDAQ:EGRX) Dividends: History, Yield and DatesFebruary 9, 2024 | prnewswire.comEAGLE PHARMACEUTICALS SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Eagle Pharmaceuticals To Contact Him Directly To Discuss Their OptionsFebruary 8, 2024 | stockhouse.comThe Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Eagle Pharmaceuticals, Inc. (EGRX)February 8, 2024 | markets.businessinsider.comLevi & Korsinsky Notifies Shareholders of Eagle Pharmaceuticals, Inc.(EGRX) of a Class Action Lawsuit and an Upcoming DeadlineSee More Headlines Receive EGRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Eagle Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/09/2021Today7/07/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:EGRX CUSIPN/A CIK827871 Webwww.eagleus.com Phone(201) 326-5300FaxN/AEmployees134Year Founded2007Price Target and Rating Average Stock Price Target$17.00 High Stock Price Target$17.00 Low Stock Price Target$17.00 Potential Upside/Downside+209.1%Consensus RatingSell Rating Score (0-4)1.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E Ratio4.66 Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$316.61 million Price / Sales0.23 Cash Flow$3.79 per share Price / Cash Flow1.45 Book Value$17.94 per share Price / Book0.31Miscellaneous Outstanding Shares12,990,000Free Float9,234,000Market Cap$71.45 million OptionableOptionable Beta0.51 Social Links A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for July 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Michael Graves (Age 61)Interim Principal Executive Officer & Executive Chairman of the Board Comp: $160kMr. Steven B. Ratoff (Age 81)Interim CFO, Principal Accounting Officer & Director Comp: $100kMr. Daniel O'Connor (Age 44)Executive VP, Chief Strategy Officer & Head of Corporate Development Dr. Valentin R. Curt M.D.Senior Vice President of Clinical Drug DevelopmentDr. Gaozhong Zhu Ph.D.Senior Vice President of Pharmaceutical DevelopmentMs. Debra M. HussainSenior VP & Head of CommercialMr. Reed McClungExecutive Vice President of Oncology Business DevelopmentMore ExecutivesKey CompetitorsZIOPHARM OncologyNASDAQ:ZIOPSpectrum PharmaceuticalsNASDAQ:SPPIALX OncologyNASDAQ:ALXOEnanta PharmaceuticalsNASDAQ:ENTARevance TherapeuticsNASDAQ:RVNCView All CompetitorsInsiders & InstitutionsKennedy Capital Management LLCSold 18,061 shares on 5/16/2024Ownership: 0.429%Jacobs Levy Equity Management Inc.Sold 5,353 shares on 5/16/2024Ownership: 0.079%Price T Rowe Associates Inc. MDBought 15,748 shares on 5/15/2024Ownership: 0.121%Vanguard Group Inc.Bought 2,630 shares on 5/10/2024Ownership: 4.934%Acadian Asset Management LLCSold 235,109 shares on 5/10/2024Ownership: 0.404%View All Insider TransactionsView All Institutional Transactions EGRX Stock Analysis - Frequently Asked Questions How have EGRX shares performed this year? Eagle Pharmaceuticals' stock was trading at $5.23 on January 1st, 2024. Since then, EGRX stock has increased by 5.2% and is now trading at $5.50. View the best growth stocks for 2024 here. How were Eagle Pharmaceuticals' earnings last quarter? Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) issued its earnings results on Tuesday, November, 9th. The specialty pharmaceutical company reported $0.56 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.44) by $1.00. The specialty pharmaceutical company had revenue of $39.85 million for the quarter, compared to analysts' expectations of $46.70 million. How do I buy shares of Eagle Pharmaceuticals? Shares of EGRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Eagle Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Eagle Pharmaceuticals investors own include Gilead Sciences (GILD), Exelixis (EXEL), Teekay Tankers (TNK), AbbVie (ABBV), Intercept Pharmaceuticals (ICPT), Radius Recycling (RDUS) and bluebird bio (BLUE). This page (NASDAQ:EGRX) was last updated on 7/8/2024 by MarketBeat.com Staff From Our PartnersWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredOperation Replace Biden is a GoLast night’s debate proved me right: Joe Biden will be replaced. I’ve been making this warning for months… ...The Freeport Society | SponsoredBiden to drop out; finish out his term?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in...Paradigm Press | SponsoredExposed: 3 CENT Crypto to Explode June 24th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredObama’s DNC coupAs we approach the Democratic National Convention in August... many sense a Biden swap-out is looming. In f...Stansberry Research | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredGrab Your Free Bitcoin Today!And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a v...Crypto Swap Profits | SponsoredAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time ...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eagle Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eagle Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free EGRX Stock Alerts